Get all your news in one place.
100's of premium titles.
One app.
Start reading
Barchart
Barchart
Kritika Sarmah

Is Wall Street Bullish or Bearish on Gilead Sciences Stock?

Valued at $147.4 billion by market cap, Gilead Sciences, Inc. (GILD) is a leading U.S. biopharmaceutical company headquartered in Foster City, California. The company specializes in treatments for HIV/AIDS, hepatitis B and C, COVID-19, and other serious infectious diseases, along with oncology and inflammatory diseases as growing focus areas. 

Shares of this HIV giant have outperformed the broader market over the past year. GILD has gained 34.2% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 17.4%. In 2025, GILD stock is up 28.2%, surpassing the SPX’s 16% rise on a YTD basis. 

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.